UCB finds buyer for US generics business despite methylphenidate uncertainties
This article was originally published in Scrip
Belgian pharma company UCB S.A. has finally found a buyer for its US generics business Kremers Urban Pharmaceuticals Inc., after a deal with private equity firms Advent International and Avista Capital Partners fell through last year. Lannett Company Inc. will pay the Belgian firm $1.23bn in cash plus certain contingent payments.
Register for our free email digests: